International Conferences


Recommended Conferences for Atypical Antipsychotics

Atypical Antipsychotics

Omics International publishes 304 Open Access Articles in 13 International Journals it has 32 Upcoming Conferences and 15 Previous Conferences with 581 Conference Proceedings and 92 National symposiums.

The data on side effects were tabulated for patients taking at least one of the following atypical antipsychotic medications: paliperidone,olanzapine, quetiapine, risperidone, aripiprazole, or ziprasidone. As a result of taking an atypical antipsychotic medication approximately there is 54% of the 353 respondents have experienced a side effect. Most common side effects includes: weight tiredness/lethargy, gain/hunger, and lack of coordination/muscle problems, such as twitches, tenderness, and tremors.The atypical antipsychotics (AAP) (otherwise called Second Generation Antipsychotic Medications (SGAs) are a group of medications used for treating some psychiatric conditions. Some SGAs are FDA-approved for use in the treatment of acute mania, bipolar disorder, schizophrenia, and bipolar mania and other mental illness conditions.

OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker. 

Second Generation Antipsychotic Medications (SGAs) are also referred to as atypical antipsychotics. The term "atypical" refers fact that they generally do not cause the same degree of movement side effects that are common to the first generation, or so-called “typical" antipsychotics. The major players in the antipsychotics market include AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, Pfizer, and GlaxoSmithKline. Eli Lilly's Zyprexa has the largest market share of the market, at 27% ($4.72 billion), while AstraZeneca's Seroquel, at 2nd place ($4.45 billion) remains the most widely prescribed antipsychotic. Bristol-Myers Squibb's Abilify, which was approved for market release in 2007, saw a 31% growth in sales from 2007 to 2008 to $2.15 billion, making it the fastest growing therapeutic in the antipsychotics market.

Antipsychotic medications are now the largest-selling class of drugs in the U.S. They have grown from a niche product to the king of blockbusters, accounting for more than $14.6 billion in annual sales.

List of Best International Conferences

Related Associations and Societies

The Society for Neuroscience

 Society for Neuro-Oncology

American Physiological Society (APS) 

American Medical Associations

American Autonomic society

America cancer society

Euro CNS

Canadian nuclear society

Health and Canadian Society

American Clinical Neurophysiology Society

American Academy of Neurology

European Neurological Societies

World Federation of Neurology

Spanish Society of Neurology

Hilarescere Foundation in Italy

Italian MS society in Italy   

Southern Clinical Neurological Society

ESNR European Society of Neuroradiology

Vision sciences society

American Association of Neurological Surgeons

Saudi Association of Neurosurgery

Emirates Medical Association

Top Market key players:

AstraZeneca plc

Eli Lilly & Co.

Johnson & Johnson



Novartis AG,


Merck & Co.,

Abbott Laboratories,


Bristol-Meyers Squibb Co.

Astellas Pharma

Cordis Corporation

Boston Scientific Corporation

Siemens AG

Genentech, Inc.

Koninklijke Philips N.V.

Medtronic plc

GE Healthcare

Stryker Corporation


Impax labs



Forest Laboratories

Chelsea therapeutics

 Upshers-smith laboratories

The World Health Organization (WHO) shows that 6.8 million people die every year as a result of neurological disorders, in Europe the economic cost of neurological diseases was estimated at about 139 billion euros in 2004. Total European 2010 cost of brain disorders was €798 billion and will grow to $480 billion by 2030

This page will be updated regularly.

This page was last updated on December 1, 2023